88 related articles for article (PubMed ID: 21946247)
1. Unravelling the epigenomic dimension of breast cancers.
Dedeurwaerder S; Fumagalli D; Fuks F
Curr Opin Oncol; 2011 Nov; 23(6):559-65. PubMed ID: 21946247
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of the sulfotransferase 1A1 gene by hypermethylation in breast tissue.
Kwon MS; Kim SJ; Lee SY; Jeong JH; Lee ES; Kang HS
Oncol Rep; 2006 Jan; 15(1):27-32. PubMed ID: 16328031
[TBL] [Abstract][Full Text] [Related]
3. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation in histologically distinct classes of breast cancer.
Bae YK; Brown A; Garrett E; Bornman D; Fackler MJ; Sukumar S; Herman JG; Gabrielson E
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5998-6005. PubMed ID: 15447983
[TBL] [Abstract][Full Text] [Related]
5. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Martens JW; Nimmrich I; Koenig T; Look MP; Harbeck N; Model F; Kluth A; Bolt-de Vries J; Sieuwerts AM; Portengen H; Meijer-Van Gelder ME; Piepenbrock C; Olek A; Höfler H; Kiechle M; Klijn JG; Schmitt M; Maier S; Foekens JA
Cancer Res; 2005 May; 65(10):4101-17. PubMed ID: 15899800
[TBL] [Abstract][Full Text] [Related]
6. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
[TBL] [Abstract][Full Text] [Related]
7. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas.
Rønneberg JA; Tost J; Solvang HK; Alnaes GI; Johansen FE; Brendeford EM; Yakhini Z; Gut IG; Lønning PE; Børresen-Dale AL; Gabrielsen OS; Kristensen VN
Cancer Res; 2008 Jul; 68(14):5562-71. PubMed ID: 18632608
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic mechanisms regulating CYP19 transcription in human breast adipose fibroblasts.
Knower KC; To SQ; Simpson ER; Clyne CD
Mol Cell Endocrinol; 2010 Jun; 321(2):123-30. PubMed ID: 20211687
[TBL] [Abstract][Full Text] [Related]
9. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.
Rody A; Holtrich U; Solbach C; Kourtis K; von Minckwitz G; Engels K; Kissler S; Gätje R; Karn T; Kaufmann M
Endocr Relat Cancer; 2005 Dec; 12(4):903-16. PubMed ID: 16322330
[TBL] [Abstract][Full Text] [Related]
10. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
12. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer.
Li SY; Rong M; Iacopetta B
Oncol Rep; 2006 Jan; 15(1):221-5. PubMed ID: 16328059
[TBL] [Abstract][Full Text] [Related]
13. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
14. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells.
Ikeda JI; Morii E; Kimura H; Tomita Y; Takakuwa T; Hasegawa JI; Kim YK; Miyoshi Y; Noguchi S; Nishida T; Aozasa K
J Pathol; 2006 Sep; 210(1):75-84. PubMed ID: 16823897
[TBL] [Abstract][Full Text] [Related]
17. Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers.
Archey WB; McEachern KA; Robson M; Offit K; Vaziri SA; Casey G; Borg A; Arrick BA
Oncogene; 2002 Oct; 21(46):7034-41. PubMed ID: 12370825
[TBL] [Abstract][Full Text] [Related]
18. Association between frequent CpG island methylation and HER2 amplification in human breast cancers.
Terada K; Okochi-Takada E; Akashi-Tanaka S; Miyamoto K; Taniyama K; Tsuda H; Asada K; Kaminishi M; Ushijima T
Carcinogenesis; 2009 Mar; 30(3):466-71. PubMed ID: 19168584
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation analysis using CpG microarrays is impaired in benzopyrene exposed cells.
Sadikovic B; Andrews J; Rodenhiser DI
Toxicol Appl Pharmacol; 2007 Dec; 225(3):300-9. PubMed ID: 17904174
[TBL] [Abstract][Full Text] [Related]
20. CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer.
Li X; Cowell JK; Sossey-Alaoui K
Oncogene; 2004 Feb; 23(7):1474-80. PubMed ID: 14973555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
